These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36637538)

  • 1. The use of calgranulin-C (S100A12) and fecal zonulin as possible non-invasive markers in children with inflammatory bowel disease: a clinical study.
    Cenni S; Casertano M; Trani M; Pacella D; Martinelli M; Staiano A; Miele E; Strisciuglio C
    Eur J Pediatr; 2023 Mar; 182(3):1299-1308. PubMed ID: 36637538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New noninvasive biomarkers of intestinal inflammation and increased intestinal permeability in pediatric inflammatory bowel diseases and their correlation with fecal calprotectin: a pilot study.
    Szymanska E; Bierla J; Dadalski M; Wierzbicka A; Konopka E; Cukrowska B; Kierkus J
    Minerva Gastroenterol (Torino); 2023 Dec; 69(4):504-510. PubMed ID: 35436840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
    Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
    Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
    Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
    Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
    Yang Z; Clark N; Park KT
    Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
    Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
    J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12.
    Däbritz J; Langhorst J; Lügering A; Heidemann J; Mohr M; Wittkowski H; Krummenerl T; Foell D
    Inflamm Bowel Dis; 2013 May; 19(6):1130-8. PubMed ID: 23377171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients.
    Cannatelli R; Bazarova A; Zardo D; Nardone OM; Shivaji U; Smith SCL; Gkoutos G; Ricci C; Gui XS; Ghosh S; Iacucci M
    Inflamm Bowel Dis; 2021 Apr; 27(5):647-654. PubMed ID: 32592477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
    Sidler MA; Leach ST; Day AS
    Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission.
    Bodini G; Ghezzi A; Pasta A; Marabotto E; Calabrese F; Facchini C; Demarzo MG; Giannini EG
    J Gastrointestin Liver Dis; 2023 Dec; 32(4):438-443. PubMed ID: 38147604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal Human Neutrophil Peptide Levels Correlate with Intestinal Inflammation in Ulcerative Colitis.
    Kanmura S; Hamamoto H; Morinaga Y; Oda K; Fujita T; Arima S; Nasu Y; Sasaki F; Hashimoto S; Taguchi H; Setoyama H; Ido A
    Digestion; 2016; 93(4):300-8. PubMed ID: 27220673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity.
    Lee YW; Lee KM; Lee JM; Chung YY; Kim DB; Kim YJ; Chung WC; Paik CN
    Korean J Intern Med; 2019 Jan; 34(1):72-80. PubMed ID: 29347813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal S100A12: a novel noninvasive marker in children with Crohn's disease.
    de Jong NS; Leach ST; Day AS
    Inflamm Bowel Dis; 2006 Jul; 12(7):566-72. PubMed ID: 16804393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
    Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
    Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients.
    Lin WC; Wong JM; Tung CC; Lin CP; Chou JW; Wang HY; Shieh MJ; Chang CH; Liu HH; Wei SC;
    World J Gastroenterol; 2015 Dec; 21(48):13566-73. PubMed ID: 26730169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease.
    Walkiewicz D; Werlin SL; Fish D; Scanlon M; Hanaway P; Kugathasan S
    Inflamm Bowel Dis; 2008 May; 14(5):669-73. PubMed ID: 18240279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.